Chemokines as effector and target molecules in vascular biology.

Chemokines are key mediators of inflammation. In pathological tissues, the main roles of chemokines are to regulate leucocyte accumulation through the activation of oriented cell migration and the activation of limited programs of gene transcription. Through these activities, chemokines exert many crucial functions, including the regulation of angiogenesis. The 'chemokine system' is tightly regulated at several levels, such as the post-transcriptional processing of ligands, the regulation of the expression and function of the receptors and through the expression of molecules known as 'atypical chemokine receptors', proteins that function as chemokine scavenging and presenting molecules. Several experimental evidence obtained in vitro, in animal models and in human studies, has defined a crucial role of chemokines in cardiovascular diseases. An intense area of research is currently exploring the possibility to develop new effective therapeutic strategies through the identification of chemokine receptor antagonists.

[1]  R. Solari,et al.  "Chemokine receptors as therapeutic targets: Why aren't there more drugs?". , 2015, European journal of pharmacology.

[2]  S. Sozzani,et al.  Chemokines as relay signals in human dendritic cell migration: Serum amyloid A kicks off chemotaxis , 2015, European journal of immunology.

[3]  M. Smit,et al.  Cutting Edge: GPR35/CXCR8 Is the Receptor of the Mucosal Chemokine CXCL17 , 2015, The Journal of Immunology.

[4]  S. Schulz,et al.  CXCL14 is no direct modulator of CXCR4 , 2014, FEBS letters.

[5]  R. Gamelli,et al.  Chemokine (C-X-C Motif) Receptor 4 and Atypical Chemokine Receptor 3 Regulate Vascular α1-Adrenergic Receptor Function , 2014, Molecular medicine.

[6]  C. Parent,et al.  New paradigms in the establishment and maintenance of gradients during directed cell migration. , 2014, Current opinion in cell biology.

[7]  Samantha L. Hoopes,et al.  Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development. , 2014, Developmental cell.

[8]  J. Shelhamer,et al.  The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce prostaglandin E2 and plays an anti‐inflammatory role in macrophages , 2014, Immunology.

[9]  S. Sozzani,et al.  LXR‐dependent and ‐independent effects of oxysterols on immunity and tumor growth , 2014, European journal of immunology.

[10]  P. Hevezi,et al.  CXCL17 Is a Major Chemotactic Factor for Lung Macrophages , 2014, The Journal of Immunology.

[11]  C. Mackay,et al.  Diet, metabolites, and "western-lifestyle" inflammatory diseases. , 2014, Immunity.

[12]  C. Weber,et al.  The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease , 2014, Front. Physiol..

[13]  A. IJzerman,et al.  Bias in chemokine receptor signalling. , 2014, Trends in immunology.

[14]  T. Hara,et al.  CXCL14 antagonizes the CXCL12-CXCR4 signaling axis , 2014, Biomolecular concepts.

[15]  A. Luster,et al.  Chemokines and chemokine receptors: positioning cells for host defense and immunity. , 2014, Annual review of immunology.

[16]  M. V. van Zandvoort,et al.  Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue , 2014, Circulation.

[17]  S. Sozzani,et al.  Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells. , 2014, Immunobiology.

[18]  J. Tao,et al.  CXCR7 Upregulation Is Required for Early Endothelial Progenitor Cell–Mediated Endothelial Repair in Patients With Hypertension , 2014, Hypertension.

[19]  A. Mantovani,et al.  International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors , 2014, Pharmacological Reviews.

[20]  S. Sozzani,et al.  Angiogenic and antiangiogenic chemokines. , 2014, Chemical immunology and allergy.

[21]  Q. Wu,et al.  Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma , 2013, Oncogene.

[22]  S. Rajagopal,et al.  Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors* , 2013, The Journal of Biological Chemistry.

[23]  R. Nibbs,et al.  Immune regulation by atypical chemokine receptors , 2013, Nature Reviews Immunology.

[24]  A. Dart,et al.  Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells , 2013, PloS one.

[25]  P. Tewary,et al.  Alarmin‐induced cell migration , 2013, European journal of immunology.

[26]  A. Mantovani,et al.  β-Arrestin–Dependent Activation of the Cofilin Pathway Is Required for the Scavenging Activity of the Atypical Chemokine Receptor D6 , 2013, Science Signaling.

[27]  J. Gustafsson,et al.  The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils , 2013, The Journal of experimental medicine.

[28]  D. Guo,et al.  Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7* , 2013, The Journal of Biological Chemistry.

[29]  E. Borroni,et al.  Atypical chemokine receptors: from silence to sound. , 2013, Biochemical Society transactions.

[30]  R. Leurs,et al.  β-Arrestin Recruitment and G Protein Signaling by the Atypical Human Chemokine Decoy Receptor CCX-CKR* , 2013, The Journal of Biological Chemistry.

[31]  C. Luo,et al.  CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. , 2013, American journal of physiology. Endocrinology and metabolism.

[32]  A. Richmond,et al.  The Chemokine Receptors CXCR1 and CXCR2 Couple to Distinct G Protein-Coupled Receptor Kinases To Mediate and Regulate Leukocyte Functions , 2012, The Journal of Immunology.

[33]  B. Lévy,et al.  The Chemokine Decoy Receptor D6 Prevents Excessive Inflammation and Adverse Ventricular Remodeling After Myocardial Infarction , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Mantovani,et al.  The biochemistry and biology of the atypical chemokine receptors. , 2012, Immunology letters.

[35]  J. Van Damme,et al.  Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. , 2012, Immunology letters.

[36]  P. Proost,et al.  Overview of the mechanisms regulating chemokine activity and availability. , 2012, Immunology letters.

[37]  C. Martínez-A,et al.  Chemokine receptor oligomerization: a further step toward chemokine function. , 2012, Immunology letters.

[38]  H. Toh,et al.  Evolutionary Analysis of Functional Divergence among Chemokine Receptors, Decoy Receptors, and Viral Receptors , 2012, Front. Microbio..

[39]  M. Selman,et al.  CXCL17 Is a Mucosal Chemokine Elevated in Idiopathic Pulmonary Fibrosis That Exhibits Broad Antimicrobial Activity , 2012, The Journal of Immunology.

[40]  U. V. von Andrian,et al.  Chemokine Guidance of Central Memory T Cells Is Critical for Antiviral Recall Responses in Lymph Nodes , 2012, Cell.

[41]  L. Varani,et al.  HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.

[42]  A. Magiera,et al.  HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. , 2012, Blood.

[43]  Michael H. Preuss,et al.  RANTES/CCL5 and Risk for Coronary Events: Results from the MONICA/KORA Augsburg Case-Cohort, Athero-Express and CARDIoGRAM Studies , 2011, PloS one.

[44]  M. Febbraio,et al.  Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. , 2011, Journal of molecular and cellular cardiology.

[45]  T. Schall,et al.  Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.

[46]  Borna Mehrad,et al.  Chemokines as mediators of tumor angiogenesis and neovascularization. , 2011, Experimental cell research.

[47]  P. Proost,et al.  Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. , 2011, Experimental cell research.

[48]  J. Van Damme,et al.  The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. , 2011, Cytokine & growth factor reviews.

[49]  A. Luster,et al.  CXCR3 ligands: redundant, collaborative and antagonistic functions , 2011, Immunology and cell biology.

[50]  M. Parmentier,et al.  Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. , 2011, Blood.

[51]  M. Hristov,et al.  Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment , 2010, Journal of cellular and molecular medicine.

[52]  Silvano Sozzani,et al.  Nomenclature of monocytes and dendritic cells in blood. , 2010, Blood.

[53]  S. Sozzani,et al.  Trafficking properties of plasmacytoid dendritic cells in health and disease. , 2010, Trends in immunology.

[54]  B. Adams Faculty Opinions recommendation of Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. , 2010 .

[55]  T. Akasaka,et al.  Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[56]  A. Mantovani,et al.  Chemokine decoy receptors: structure-function and biological properties. , 2010, Current topics in microbiology and immunology.

[57]  R. Strieter,et al.  CXC chemokines in cancer angiogenesis and metastases. , 2010, Advances in cancer research.

[58]  R. Lefkowitz,et al.  β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7 , 2009, Proceedings of the National Academy of Sciences.

[59]  M. Parmentier,et al.  Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.

[60]  Robert J. Lefkowitz,et al.  Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands , 2009, Proceedings of the National Academy of Sciences.

[61]  F. Baleux,et al.  CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. , 2009, Blood.

[62]  F. Moll,et al.  Carotid Atherosclerotic Plaques Stabilize After Stroke: Insights Into the Natural Process of Atherosclerotic Plaque Stabilization , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[63]  Athena,et al.  G Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment during Intestinal Inflammation , 2009 .

[64]  T. Handel,et al.  Modulation of chemokine receptor activity through dimerization and crosstalk , 2009, Cellular and Molecular Life Sciences.

[65]  M. Parmentier,et al.  Synergy between Coproduced CC and CXC Chemokines in Monocyte Chemotaxis through Receptor-Mediated Events , 2008, Molecular Pharmacology.

[66]  Tullio Pozzan,et al.  CXCR4–CCR5: A couple modulating T cell functions , 2008, Proceedings of the National Academy of Sciences.

[67]  T. Simon,et al.  Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice , 2008, Circulation.

[68]  Erez Raz,et al.  Control of Chemokine-Guided Cell Migration by Ligand Sequestration , 2008, Cell.

[69]  Johan Kuiper,et al.  CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[70]  H. Sarau,et al.  CXCR2 Blockade Impairs Angiotensin II–Induced CC Chemokine Synthesis and Mononuclear Leukocyte Infiltration , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[71]  H. Putter,et al.  CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms , 2007, Circulation.

[72]  Richard P. Harvey,et al.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.

[73]  N. Frangogiannis Chemokines in ischemia and reperfusion , 2007, Thrombosis and Haemostasis.

[74]  Patrick W Serruys,et al.  Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines. , 2007, The Journal of clinical investigation.

[75]  B. Haribabu,et al.  Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. , 2007, Blood.

[76]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[77]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[78]  A. Tedgui,et al.  Role of Bone Marrow–Derived CC-Chemokine Receptor 5 in the Development of Atherosclerosis of Low-Density Lipoprotein Receptor Knockout Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[79]  M. Baba,et al.  Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. , 2006, Journal of medicinal chemistry.

[80]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[81]  R. Terkeltaub,et al.  Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. , 2006, The American journal of pathology.

[82]  G. Frantz,et al.  Cutting Edge: Novel Human Dendritic Cell- and Monocyte-Attracting Chemokine-Like Protein Identified by Fold Recognition Methods , 2006, The Journal of Immunology.

[83]  R. Schuster,et al.  The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  A. Mantovani,et al.  Migration of dendritic cells across blood and lymphatic endothelial barriers , 2005, Thrombosis and Haemostasis.

[85]  Eric Reiter,et al.  GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. , 2006, Trends in endocrinology and metabolism: TEM.

[86]  H. Fujiwara,et al.  HIV Entry Inhibitor TAK-779 Attenuates Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[87]  C. Mackay,et al.  Gene Profiling in Atherosclerosis Reveals a Key Role for Small Inducible Cytokines: Validation Using a Novel Monocyte Chemoattractant Protein Monoclonal Antibody , 2005, Circulation.

[88]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[89]  A. El‐Naggar,et al.  BRAK/CXCL14 Is a Potent Inhibitor of Angiogenesis and a Chemotactic Factor for Immature Dendritic Cells , 2004, Cancer Research.

[90]  I. Charo,et al.  Chemokines in the pathogenesis of vascular disease. , 2004, Circulation research.

[91]  B. Haribabu Leukotrienes: Novel targets for vascular disease. , 2004, Discover medicine.

[92]  W. März,et al.  Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. , 2004, European heart journal.

[93]  D. Greaves,et al.  The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics , 2004, Current opinion in lipidology.

[94]  U. V. von Andrian,et al.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.

[95]  H. Baba,et al.  Cloning of a G‐protein‐coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells , 2004, Cancer science.

[96]  D. Greaves,et al.  Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX3CR1 and Undergo Chemotaxis to the CX3C Chemokine Fractalkine (CX3CL1) , 2003, Circulation.

[97]  D. Ribatti,et al.  Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis1 , 2003, The Journal of Immunology.

[98]  M. Parmentier,et al.  Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation* , 2003, Journal of Biological Chemistry.

[99]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[100]  R. D'Agostino,et al.  Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. , 2003, The Journal of clinical investigation.

[101]  Ravindra Uppaluri,et al.  Cutting Edge: IFN-Producing Cells Respond to CXCR3 Ligands in the Presence of CXCL12 and Secrete Inflammatory Chemokines upon Activation1 , 2002, The Journal of Immunology.

[102]  R. Ransohoff,et al.  The Chemokine Receptor CXCR2 Controls Positioning of Oligodendrocyte Precursors in Developing Spinal Cord by Arresting Their Migration , 2002, Cell.

[103]  S. Frøland,et al.  Stromal Cell–Derived Factor-1&agr; in Unstable Angina: Potential Antiinflammatory and Matrix-Stabilizing Effects , 2002, Circulation.

[104]  R. Strieter,et al.  Potential role for Duffy antigen chemokine‐binding protein in angiogenesis and maintenance of homeostasis in response to stress , 2002, Journal of leukocyte biology.

[105]  S. Frøland,et al.  Chemokines in myocardial failure – pathogenic importance and potential therapeutic targets , 2001, Clinical and experimental immunology.

[106]  P. Allavena,et al.  Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys , 2000, Nature Immunology.

[107]  A. Richmond,et al.  Delayed wound healing in CXCR2 knockout mice. , 2000, The Journal of investigative dermatology.

[108]  G. McFadden,et al.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. , 2000, The Journal of clinical investigation.

[109]  P. Allavena,et al.  Hepatocyte Growth Factor (HGF) Stimulates Tumor Cells to Release Chemokines Active in Recruiting Dendritic Cells , 2000 .

[110]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[111]  P. Allavena,et al.  The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. , 1998, Blood.

[112]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[113]  R Bonecchi,et al.  Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. , 1998, Journal of immunology.

[114]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[115]  A. Mantovani,et al.  Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. , 1994, Journal of immunology.

[116]  W. Wood,et al.  Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. , 1994, Science.

[117]  A. Rot Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. , 1992, Immunology today.

[118]  A. Fogelman,et al.  Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.